Visiopharm
Visiopharm image analysis and stereology software has become the preferred Quantitative Digital Pathology solution.
- B2B
- saas
- subscription
- health
- health platform
- artificial intelligence
- big data
- deep tech
- machine learning
- augmented reality
- deep learning
- nanotech
- computer vision
- dt and ls
- core ai
- analytics
- ai applications
- immersive technologies
- oncology
- ai agents
- health it
- nordic rising star 2022
- tech for hospitals and clinics
- tech for medical professionals
- health diagnostics
- physician support tools
- medical imaging
- clinical decision support
- ai for medical imaging
- tissue engineering
- pathology
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
N/A | Late VC | ||
| Total Funding | 000k | ||
| EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (17 %) | 57 % | (15 %) | 45 % | 25 % | (18 %) | 5 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (21 %) | (25 %) | (35 %) | (38 %) | (15 %) | (27 %) | (15 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
In 2001, Johan Dore and Michael Grunkin founded Visiopharm in Denmark, setting out to revolutionize the field of digital pathology. Their vision was to harness the power of AI to enhance image analysis and workflow standardization in pathology labs. This innovation aimed to improve diagnostic accuracy and efficiency, addressing a critical need in medical diagnostics.
Visiopharm's journey was marked by strategic growth and innovation. In 2016, the company expanded its capabilities by acquiring LRI Instrument AB, a move that strengthened its technological foundation and broadened its market reach. This acquisition was a pivotal moment, enabling Visiopharm to offer more comprehensive solutions to its clients.
Over the years, Visiopharm secured significant funding to fuel its growth. By 2025, the company had raised a total of $26.3 million over several funding rounds, attracting investments from notable entities like ATP and BankInvest. This financial backing was crucial in supporting Visiopharm's research and development efforts, allowing it to stay at the forefront of digital pathology innovation.
Today, Visiopharm stands as a leader in the field, known for its cutting-edge AI-driven solutions that empower pathologists worldwide. The company's commitment to advancing medical diagnostics continues to drive its success, making it a key player in the healthcare technology landscape.
Tech stack
Investments by Visiopharm
Edit